--- a
+++ b/clusters/9knumclustersv2/clust_1552.txt
@@ -0,0 +1,65 @@
+Angina, myocardial infarction, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism , pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) within  months prior to randomization. Deep venous thrombosis within  months prior to randomization unrelated to a central venous catheter, unless the patient is anti-coagulated without the use of warfarin for at least  weeks prior to randomization. In this situation, low molecular weight heparin is preferred
+A history of cardiovascular diseases: unstable angina, myocardial infarction, or known congestive heart failure class IIIV within the preceding  months; cerebrovascular accident or transient ischemic attack within the preceding  months, pulmonary embolism within the preceding  months
+Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past  months.
+Any of the following cardiovascular history in the past  months: myocardial infarction, unstable angina, coronary/ peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, symptomatic bradycardia, requirement for anti-arrhythmic medication.
+Uncontrolled congestive heart failure (New York Heart Association Classification  or ), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within  months prior to initiation of study drug.
+Any of the following in the previous  months:\r\n* Myocardial infarction\r\n* Severe/unstable angina\r\n* Coronary/peripheral artery bypass graft\r\n* Symptomatic congestive heart failure\r\n* Cerebrovascular accident\r\n* Transient ischemic attack\r\n* Symptomatic pulmonary embolism
+Uncontrolled intercurrent illness including, but not limited to ongoing or active infection. Any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
+Any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack
+Have experienced any of the following within the -month period prior to Screening: unstable angina pectoris, clinically significant coronary artery disease, cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection fraction less than %, or cardiac arrhythmia
+Subjects with the following cardiac risk factors must be excluded: transmural myocardial infarction (MI) within prior  months, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack (TIA) or seizure disorder within  months prior to study drug administration; in addition, patients with New York Heart Association (NYHA) class III or IV heart failure will be excluded
+Any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
+Diagnosis with any of the following in the  months prior to registration: severe/unstable angina, myocardial infarction, uncontrolled cardiac arrhythmia, congestive heart failure, cerebrovascular accident or transient ischemic attack
+Any of the following within the  months prior to registration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack
+Any of the following within  months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
+Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within  months prior to study treatment
+Uncontrolled intercurrent illness including, but not limited to ongoing or active infection; any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism
+Within the past  months, has had any of the following: pleural effusion, myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
+Within the past  months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
+Any of the following within the  months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack
+Any of the following within  months of registration: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= , atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism; no QTc interval >  msec, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or torsade de pointes
+Any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism
+CAPMATINIB EXCLUSION CRITERIA: Any of the following in the past  months prior to screening:\r\n* Myocardial infarction\r\n* Severe/unstable angina\r\n* Clinically significant cardiac arrhythmias\r\n* Cerebrovascular accident or transient ischemic attack\r\n* Coronary/peripheral artery bypass graft
+CERITINIB EXCLUSION CRITERIA: Any of the following in the past  months prior to screening:\r\n* Myocardial infarction\r\n* Severe/unstable angina\r\n* Clinically significant cardiac arrhythmias\r\n* Cerebrovascular accident or transient ischemic attack\r\n* Coronary/peripheral artery bypass graft
+REGORAFENIB EXCLUSION CRITERIA: Any of the following in the past  months prior to screening:\r\n* Myocardial infarction\r\n* Severe/unstable angina\r\n* Clinically significant cardiac arrhythmias\r\n* Cerebrovascular accident or transient ischemic attack\r\n* Coronary/peripheral artery bypass graft
+ENTRECTINIB EXCLUSION CRITERIA: Any of the following in the past  months prior to screening:\r\n* Myocardial infarction\r\n* Severe/unstable angina\r\n* Clinically significant cardiac arrhythmias\r\n* Cerebrovascular accident or transient ischemic attack\r\n* Coronary/peripheral artery bypass graft
+Any of the following within  months prior to study enrollment: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE grade >= , symptomatic congestive heart failure, or cerebrovascular accident excluding transient ischemic attack
+Any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, LVEF less than LLN, clinically significant pericardial effusion, cerebrovascular accident, transient ischemic attack
+Coronary/peripheral artery bypass graft
+Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass surgery (CABG) within the past  months; deep venous thrombosis within  months, unless the patient is anticoagulated without the use of warfarin for at least  weeks; in this situation, low molecular weight heparin is preferred
+Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within  months prior to initiation of study drug.
+Severe cardiovascular disease within  months, including myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebro-vascular accident or transient ischemic attack, pulmonary embolism, life threatening arrhythmias, uncontrollable hypertension or QT prolongation syndrome
+Patients with symptomatic congestive heart failure, unstable angina or myocardial infarction, coronary/peripheral artery bypass graft or repair, cerebrovascular accident or transient ischemic attack in the  months prior to randomization; or deep vein thrombosis or pulmonary embolism in the  months prior to randomization
+Any of the following: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE grade >= , atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, uncontrolled seizures or brain metastases or pulmonary embolism.
+Any of the following within  months prior to first dose of treatment: myocardial infarction, symptomatic coronary artery disease (severe or unstable angina), artery bypass graft, uncontrolled arrhythmias, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolus
+Any of the following within the  months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
+Any of the following within  months of randomization: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version . Grade ?, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
+Coronary/peripheral artery bypass graft
+Any of the following within  months prior to enrollment: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of Grade greater than or equal to (>/=) , atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, or cerebrovascular accident including transient ischemic attack
+Any of the following within the  months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
+Any of the following within the  months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack
+Any of the following in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, deep vein thrombosis or symptomatic pulmonary embolism.
+Patients with any of the following conditions are excluded:\r\n* Serious or non-healing wound, ulcer, or bone fracture\r\n* History of abdominal fistula, gastrointestinal perforation, or intra- abdominal abscess within  days of treatment\r\n* Any history of cerebrovascular accident (CVA) or transient ischemic attack within  months prior to study entry\r\n* History of myocardial infarction, ventricular arrhythmia, stable/unstable angina, symptomatic congestive heart failure, coronary/peripheral artery bypass graft or stenting or other significant cardiac disease within  months prior to study entry\r\n* Any history of arterial or venous thrombosis/thromboembolic event, including pulmonary embolism within the past  months\r\n* Any episode of atrial fibrillation in the prior  months
+In past  months: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
+Any of the following within the preceding  months- myocardial infarction, severe/unstable angina, severe peripheral vascular disease (claudication) or procedure on peripheral vasculature, coronary/peripheral artery bypass, graft, cerebrovascular accident or transient ischemic attack, clinically significant bleeding
+Any of the following within  months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and within  months before study drug administration for deep vein thrombosis or pulmonary embolism
+Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction, or unstable angina pectoris within  months of screening
+Any of the following within the  months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
+Any of the following within  months prior to trial registration: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event
+Any of the following in the past  months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
+Any of the following in the past  months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
+Any one of the following currently or in the previous  months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack; symptomatic pulmonary embolism; congenital long QT syndrome, torsades de points, arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), right bundle branch block and left anterior hemiblock (bifascicular block), ongoing cardiac dysrhythmias of NCI CTCAE Grade >=, atrial fibrillation of any grade, or QTc interval > msec at screening.
+Uncontrolled hypertension (blood pressure >/ mmHg despite optimal medical therapy) or any of the following within  months prior to registration: myocardial infarction, congenital long QT syndrome, torsade de points, arrhythmias, right bundle branch block and left anterior hemiblock uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, ongoing NCICTCAE Grade  cardiac dysrhythmias, atrial fibrillation or QTcF interval > msec.
+Any of the following within  months prior to study entry:\r\n* Myocardial infarction (MI)\r\n* Severe/unstable angina\r\n* Coronary artery bypass graft (CABG)\r\n* Congestive heart failure (CHF) > New York Heart Association (NYHA) II\r\n* Cerebrovascular accident (CVA)\r\n* Transient ischemic attack (TIA)\r\n* Pulmonary embolism (PE)
+Cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within  weeks prior to Baseline.
+SUNITINIB MALATE ARM: Patients with any of the following conditions are excluded:\r\n* Serious or non-healing wound, ulcer, or bone fracture\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days of treatment\r\n* Any history of cerebrovascular accident (CVA) or transient ischemic attack within  months prior to study entry\r\n* History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within  months prior to study entry\r\n* History of pulmonary embolism within the past  months
+Any of the following within the  months prior to study drug administration: myocardial infarction, severe/unstable angina, severe peripheral vascular disease (claudication) or procedure on peripheral vasculature, coronary/peripheral artery bypass graft, New York Heart Association grade II or greater congestive heart failure, cerebrovascular accident or transient ischemic attack, clinically significant bleeding or pulmonary embolism
+Any of the following in the past  months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV), cerebrovascular accident, transient ischemic attack, other arterial thromboembolic event, or pulmonary embolism
+Any of the following within the  months prior to registration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and  months for deep vein thrombosis or pulmonary embolism.
+Have experienced any of the following within the -month period prior to screening: angina pectoris, coronary artery disease or cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection fraction less than %, or cardiac arrhythmia requiring medical therapy
+Coronary or peripheral artery bypass graft within  months of screening
+Any of the following within  months prior to study drug administration: myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
+Have experienced any of the following within the -month period prior to screening: angina pectoris, coronary artery disease or cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection fraction less than %, or severe uncontrolled ventricular arrhythmia.
+Any of the following within the  months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack.
+Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial infarction.
+Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) within the past  months. Deep venous thrombosis within  months, unless the patient is therapeutically anti-coagulated for at least  weeks. In this situation, low molecular weight heparin is preferred